Cloud Banner

Healthcare

Image

Global Hospital Acquired Disease Testing Market – Industry Trends and Forecast to 2030

  • Healthcare
  • Upcoming Report
  • Dec 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Hospital Acquired Disease Testing Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR - 16.900000000000002% Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 10.30 Billion
Diagram Market Size (Forecast Year) USD 35.92 Billion
Diagram CAGR 16.900000000000002%

Global Hospital Acquired Disease Testing Market, By Test Type (Urinary Tract Infection, Surgical Site Infection, Pneumonia Stents, Blood Stream Infection, Methicillin-Resistant Staphylococcus Aureus, Others), End User (Hospitals and Intensive Care Units (ICUS), Ambulatory Surgical and Diagnostic Centers, Nursing Homes and Maternity Centers) – Industry Trends and Forecast to 2030.

Hospital Acquired Disease Testing Market Analysis and Size

The rising number of patients suffering from nosocomial infections, the government's increasing number of regulations to penalise hospitals, extended hospitalization and antibody resistance, the growth of the medical tourism industry, and the prevalence of modernized healthcare infrastructure are some of the major and impactful factors that will likely drive the growth of the hospital acquired disease testing market during the forecast period of 2023-2030. On the other hand, the development of various technologies and the increasing number of research and development activities by various companies will provide abundant opportunities, leading to the growth of the hospital acquired disease testing market during the forecast period.

Data Bridge Market Research analyses that the hospital acquired disease testing market which is USD 10.3 billion in 2022, is expected to reach USD 35.92 billion by 2030, at a CAGR of 16.90% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Hospital Acquired Disease Testing Market Scope and Segmentation  

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Test Type (Urinary Tract Infection, Surgical Site Infection, Pneumonia Stents, Blood Stream Infection, Methicillin-Resistant Staphylococcus Aureus, Others), End User (Hospitals and Intensive Care Units (ICUS), Ambulatory Surgical and Diagnostic Centers, Nursing Homes and Maternity Centers)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Abbott (U.S.), Eurofins Scientific (Luxembourg), BIOMÉRIEUX (France), Cantel Medical (U.S.), Meridian Bioscience, Inc. (U.S.), QIAGEN (Germany), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S.), Hologic, Inc. (U.S.), Siemens Healthcare Private Limited (Germany), Thermo Fisher Scientific Inc. (U.S.), Medtronic (Ireland), Getinge AB (Sweden), Olympus Corporation (Japan), 3M (U.S.), Luminex Corporation (U.S.), Diatherix Laboratories (U.S.), Life Technologies (U.S.), Cepheid Inc. (U.S.)

Market Opportunities

  • Establishment of government guidelines

Market Definition

Health care professionals, particularly clinical laboratory technicians, use hospital acquired disease testing to diagnose nosocomial infection. Healthcare professionals, particularly clinical laboratory technicians, use hospital acquired disease testing to diagnose nosocomial infections. The hospital acquired infection testing market has grown rapidly over the last decade, owing to factors such as increased awareness about the global increase in the incidence of nosocomial infections and the development of innovative prevention and treatment solutions.

Hospital Acquired Disease Testing Market Dynamics

Drivers

  • Growing prevalence of HAIs

The market for hospital acquired disease testing is currently growing at a double-digit rate. The global number of health care facilities has increased significantly as a result of rising population and modernization of healthcare infrastructure. As a result, the prevalence of HAIs has increased, increasing the demand for hospital acquired disease tests. Furthermore, with advanced technologies and scientific innovations, various techniques for diagnosing, preventing,  and monitoring HAIs, such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs) and solid phase hybridization, are now available on the market. Techniques like RTLS make it simple to keep HAIs from spreading among patients and staff. These are the certain factors which propel the market growth.

  • Rise in the number of drug resistant pathogens

Rapid and efficient infection detection solutions help reduce the incidence of nosocomial infections and overall medical costs, hospital stays, and death. The widespread availability of more sophisticated infection detection solutions, particularly those under molecular diagnostics, as well as their demonstrated efficiency in delivering faster results, has increased demand for such products worldwide. Demand for hospital acquired government initiatives are driving infection testing and hospital acquired infection controlling authorities focusing on spreading awareness about hospital acquired infection and available treatments. As a result, the rise in drug-resistant pathogens and the prevalence of hospital acquired infections are driving the growth of the hospital acquired infection testing market.

Opportunities

  • Establishment of government guidelines

According to the US Department of Health and Human Services, hospital acquired infection prevention costs between $28.0 billion and $33.0 billion per year. Governments are taking steps to reduce hospital acquired infection prevalence in their respective countries in order to reduce the burden on hospitals caused by patients' prolonged hospital stays. Hospital acquired infection prevention and control authorities exist in developed countries, with established guidelines for detection and treatment of hospital acquired infection. For instance, the Centers for Disease Control and Prevention (CDC), recommends a nucleic acid amplification test for C. difficile detection, whereas the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommends a two-step detection process for C. difficile identification. In countries, these guidelines drive the market for recommended tests.

Restraints/Challenges

  • Stringent regulations and guidance framework

Stringent government regulations regarding molecular biology-based diagnostics and a lack of awareness among people in developing economies are likely to act as market restraints in the growth of hospital acquired disease testing during the forecast period.

This hospital acquired disease testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hospital acquired disease testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Hospital Acquired Disease Testing Market Scope

The hospital acquired disease testing market is segmented on the basis of test type and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Test Type

  • Urinary Tract Infection
  • Surgical Site Infection
  • Pneumonia Stents
  • Blood Stream Infection
  • Methicillin-Resistant Staphylococcus Aureus
  • Others

 End User

  • Hospitals and Intensive Care Units (ICUS)
  • Ambulatory Surgical and Diagnostic Centers
  • Nursing Homes
  •  Maternity Centers

Hospital Acquired Disease Testing Market Regional Analysis/Insights

The hospital acquired disease testing market is analyzed and market size insights and trends are provided by country, test type and end user as referenced above.

The countries covered in the hospital acquired disease testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the hospital acquired disease testing market due to an increase in the number of government initiatives aimed at reducing nosocomial infections, as well as the prevalence of favourable reimbursement policies in the region as a result of the growth of medical tourism.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the increase in the number of hospitals and the occurrences of hospital acquired infections.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The hospital acquired disease testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for hospital acquired disease testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the hospital acquired disease testing market. The data is available for historic period 2011-2021.

Competitive Landscape and Hospital Acquired Disease Testing Market Share Analysis

The hospital acquired disease testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hospital acquired disease testing market.

Some of the major players operating in the hospital acquired disease testing market are:

  • Abbott (U.S.)
  • Eurofins Scientific (Luxembourg)
  • BIOMÉRIEUX (France)
  • Cantel Medical (U.S.)
  • Meridian Bioscience, Inc. (U.S.)
  • QIAGEN (Germany)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • BD (U.S.)
  • Hologic, Inc. (U.S.)
  • Siemens Healthcare Private Limited (Germany)
  • Thermo Fisher Scientific Inc. (U.S.)
  • Medtronic (Ireland)
  • Getinge AB (Sweden)
  • Olympus Corporation (Japan)
  • 3M (U.S.)
  • Luminex Corporation (U.S.)
  • Diatherix Laboratories (U.S.)
  • Life Technologies (U.S.)
  • Cepheid Inc. (U.S.)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The Hospital Acquired Disease Testing Market is projected to grow at a CAGR of 16.90% during the forecast period by 2030.
The future market value of the Hospital Acquired Disease Testing Market is expected to reach USD 35.92 billion by 2030.
The major players in the Hospital Acquired Disease Testing Market are Abbott (U.S.), Eurofins Scientific (Luxembourg), BIOMÉRIEUX (France), Cantel Medical (U.S.), Meridian Bioscience, Inc. (U.S.), QIAGEN (Germany), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S.), etc.
The countries covered in the Hospital Acquired Disease Testing Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, etc.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials